ARTHROPLASTY
Single-shot dose and continuous infusion of TXA have similar efficacy in primary TKA
This report has been verified
by one or more authors of the
original publication.
Arch Orthop Trauma Surg. 2015 Apr;135(4):465-71
106 patients undergoing total knee arthroplasty were randomized to receive either a 30mg/kg bolus dose of tranexamic acid (TXA), or 10mg/kg dose TXA plus 2mg/kg/h continuous infusion postoperatively for 20 hours. The purpose of this study was to compare blood loss within the first week of surgery, as well as complications and clinical outcomes within the first year of surgery. The findings illustrated no significant differences between groups for any of the measured outcomes. Additionally, no venous thromboembolic events were noted in any patient of either group.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
